Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.

[1]  E. Van Cutsem,et al.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. , 2020, The Lancet. Oncology.

[2]  Y. N. Park,et al.  Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation- and proliferation-phenotypes. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[3]  V. Miller,et al.  Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). , 2019, Journal of Clinical Oncology.

[4]  T. Karlsen,et al.  Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis , 2019, Hepatology.

[5]  Zhanguo Zhang,et al.  IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC. , 2018, The Journal of surgical research.

[6]  N. Schultz,et al.  Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention , 2018, Clinical Cancer Research.

[7]  M. Fassan,et al.  Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma , 2018, Scientific Reports.

[8]  G. Getz,et al.  Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. , 2018, Journal of hepatology.

[9]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[10]  Li Ding,et al.  Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics , 2018, Cell.

[11]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Lily Hoffman-Andrews.  The known unknown: the challenges of genetic variants of uncertain significance in clinical practice , 2017, Journal of law and the biosciences.

[13]  P. Philip,et al.  Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[15]  E. Maher,et al.  Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: Results from the cholangiocarcinoma dose escalation and expansion cohorts. , 2017 .

[16]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[17]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[18]  T. Azuma,et al.  Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas , 2017, Modern Pathology.

[19]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[20]  P. Stephens,et al.  Biliary cancer: Utility of next‐generation sequencing for clinical management , 2016, Cancer.

[21]  Yoshihiro Sakamoto,et al.  Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma , 2016, The American journal of surgical pathology.

[22]  Andrew X. Zhu,et al.  Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise , 2016, The oncologist.

[23]  Darrell,et al.  Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. , 2015, The oncologist.

[24]  Hiromi Nakamura,et al.  Genomic spectra of biliary tract cancer , 2015, Nature Genetics.

[25]  M. Gonen,et al.  Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. , 2015, Journal of the American College of Surgeons.

[26]  M. Miyazaki,et al.  Intrahepatic cholangiocarcinoma: expert consensus statement. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[27]  A. Farioli,et al.  Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies , 2015, Oncotarget.

[28]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[29]  G. Mills,et al.  Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.

[30]  Nansheng Chen,et al.  Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.

[31]  Y. Jeng,et al.  Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features , 2014, Modern Pathology.

[32]  A. Ejaz,et al.  Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets , 2014, Annals of Surgical Oncology.

[33]  Y. Totoki,et al.  Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.

[34]  Swe Swe Myint,et al.  Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.

[35]  T. Pawlik,et al.  Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.

[36]  Kui Wang,et al.  Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Jesse S. Voss,et al.  Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. , 2012, Human pathology.

[38]  Derek Y. Chiang,et al.  Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.

[39]  T. Roskams,et al.  Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes , 2012, Hepatology.

[40]  Bin Tean Teh,et al.  Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.

[41]  Y. Jan,et al.  K-ras Mutation is Strongly Associated with Perineural Invasion and Represents an Independent Prognostic Factor of Intrahepatic Cholangiocarcinoma after Hepatectomy , 2012, Annals of Surgical Oncology.

[42]  L. Schwartz,et al.  Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results , 2011, Oncology.

[43]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[44]  Jing Xu,et al.  Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. , 2010, World journal of hepatology.

[45]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[46]  L. Schwartz,et al.  Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  I. Endo,et al.  Intrahepatic cholangiocarcinoma , 2014, Radiopaedia.org.

[48]  O. Matsui,et al.  A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: ‘bile ductular carcinoma’ , 2007, Histopathology.

[49]  M. Matsuda,et al.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.

[50]  Yoshihiko Maehara,et al.  Proposal of Progression Model for Intrahepatic Cholangiocarcinoma: Clinicopathologic Differences Between Hilar Type and Peripheral Type , 2007, The American journal of surgical pathology.

[51]  T. Patel.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[52]  Sedro Indqgnsiuper,et al.  Biliary , 1993, Definitions.

[53]  N. Schultz,et al.  Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. , 2019, JAMA oncology.

[54]  T. Pawlik,et al.  Intrahepatic cholangiocarcinoma: An international, multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.